Dong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong Zhang has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
Zhi-Xia Yang
Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Anhui Medical University, Hefei, China
13 shared publicationsCong-Rong Li
Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Anhui Medical University, Hefei, China
11 shared publicationsYang Wang
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei, China
11 shared publicationsZhen Jin
Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Ctr Reprod Med,Dept Gynecol, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China
8 shared publicationsLiang-Jian Chen
State Key Lab of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu, China
7 shared publicationsPeng Liu
State Key Lab of Reproductive Medicine, Nanjing Medical University, Nanjing 211166, Jiangsu, P.R. China
6 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (7) , 2368-2391
Non-reproductive tumor progression impairs ovarian function through CXCL10–IL18R1 axis
The ovary is susceptible to harmful environmental factors. Tumor progression (TP) is an intracorporal harmful environmental factor. It is known that TP could impair adjacent tissues through pro-inflammatory cytokines. However, it is unclear whether and how non-reproductive tumor progression (NRTP) impairs ovarian function. In this study, we used MCA205 (mouse fibrosarcoma) cell-allotransplanted B6 mice as a basic model (M group); meanwhile, we established two popular therapeutic models — PD-1 monoclonal antibody injection in allotransplanted mice (PD-1 group) and whole cancer cell vaccine (WCV) injection in allotransplanted mice (WCV group) — to facilitate the discovery process. As expected, TP in M group decreased ovarian function multifacetedly. Interestingly, WCV injection significantly reversed these abnormalities, whereas PD-1 did not. Next, plasma cytokine microarray characterized CXCL10 with both the biggest increment in M group and best rescue in WCV group. Next, we baited the only CXCL10 receptor, IL18R1, within ovaries. Next, we found that CXCL10 directly bound to IL18R1 to impair ovarian function through three pathways: inducing ovarian fibrosis through p-JNK→p-JUN → COL1A1, promoting primordial follicle overactivation through p-AKT→p-FOXO3A, and increasing ovarian inflammation through p-P65 → IFNγ. We have also preliminarily verified the CXCL10–IL18R1 axis and the upper three downstream pathways in MC38 (mouse colon cancer cells)-allotransplanted and B16F10 (mouse melanoma cells)-allotransplanted B6 mice. Finally, we rescued the decreased ovarian function in the M group by blocking the CXCL10 → IL18R1 pathway with CXCL10 antibody or a CXCL10–IL18R1 interface peptide, CIBB. This study provides mechanical evidence and translational strategies of how NRTP impairs ovarian functions and how to target-protect ovaries under NRTP.
- 22 July 2026
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 58 (7) , 2368-2391
Open AccessNon-reproductive tumor progression impairs ovarian function through CXCL10–IL18R1 axis
The ovary is susceptible to harmful environmental factors. Tumor progression (TP) is an intracorporal harmful environmental factor. It is known that TP could impair adjacent tissues through pro-inflammatory cytokines. However, it is unclear whether and how non-reproductive tumor progression (NRTP) impairs ovarian function. In this study, we used MCA205 (mouse fibrosarcoma) cell-allotransplanted B6 mice as a basic model (M group); meanwhile, we established two popular therapeutic models — PD-1 monoclonal antibody injection in allotransplanted mice (PD-1 group) and whole cancer cell vaccine (WCV) injection in allotransplanted mice (WCV group) — to facilitate the discovery process. As expected, TP in M group decreased ovarian function multifacetedly. Interestingly, WCV injection significantly reversed these abnormalities, whereas PD-1 did not. Next, plasma cytokine microarray characterized CXCL10 with both the biggest increment in M group and best rescue in WCV group. Next, we baited the only CXCL10 receptor, IL18R1, within ovaries. Next, we found that CXCL10 directly bound to IL18R1 to impair ovarian function through three pathways: inducing ovarian fibrosis through p-JNK→p-JUN → COL1A1, promoting primordial follicle overactivation through p-AKT→p-FOXO3A, and increasing ovarian inflammation through p-P65 → IFNγ. We have also preliminarily verified the CXCL10–IL18R1 axis and the upper three downstream pathways in MC38 (mouse colon cancer cells)-allotransplanted and B16F10 (mouse melanoma cells)-allotransplanted B6 mice. Finally, we rescued the decreased ovarian function in the M group by blocking the CXCL10 → IL18R1 pathway with CXCL10 antibody or a CXCL10–IL18R1 interface peptide, CIBB. This study provides mechanical evidence and translational strategies of how NRTP impairs ovarian functions and how to target-protect ovaries under NRTP.
- 23 June 2026
- Published by Taylor & Francis in Autophagy
- Vol. 22 (11) , 3123-3143
SNCA/synuclein alpha impairs endometrial receptivity in obesity by disrupting STUB1-TFEB-mediated autophagy
The global obesity epidemic poses significant clinical and public health challenges [1], including substantial adverse effects on reproductive health [2, 3]. In women of reproductive age, obesity i...
- 23 June 2026
- Published by Taylor & Francis in Autophagy
- Vol. 22 (11) , 3123-3143
SNCA/synuclein alpha impairs endometrial receptivity in obesity by disrupting STUB1-TFEB-mediated autophagy
The global obesity epidemic poses significant clinical and public health challenges [1], including substantial adverse effects on reproductive health [2, 3]. In women of reproductive age, obesity i...
- Open Access
- 28 April 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
PCOS combined with obesity aggravates the metabolic and immune abnormality in females
Polycystic ovary syndrome (PCOS) appears to be closely correlated with obesity; however, no studies have compared the difference between PC-Ob (PCOS plus o
- 28 April 2026
- Published by Springer Nature in BMC Women's Health
- Vol. 26 (1)
Open AccessPCOS combined with obesity aggravates the metabolic and immune abnormality in females
Polycystic ovary syndrome (PCOS) appears to be closely correlated with obesity; however, no studies have compared the difference between PC-Ob (PCOS plus o
- 13 December 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 67-79
Clinical application of preimplantation genetic testing for pathogenic microdeletion and microduplication based on an effective and convenient sequencing platform
Purpose PGT utilizing SNP-based linkage analysis for monogenic defects associated with microdeletions/duplications has been the standard method for preventing disease inheritance. However, its high cost and time consumption limit its accessibility. This study introduces a novel platform, the GenoLab M DX gene sequencer, designed to leverage next-generation sequencing (NGS) technology, aiming to reduce costs and increase sequencing efficiency in preimplantation genetic testing (PGT) for microdeletions/duplications. Methods Couples with microdeletion/duplication syndromes were recruited, and GenoLab was employed to detect copy number variations (CNVs) under 4 Mb in their abnormal blastocysts, developmentally arrested embryos, and peripheral blood, assessing the diagnostic validity of GenoLab. Results Blastocysts and arrested embryos from eight couples were thawed and sequenced using GenoLab. Of 69 affected blastocyst samples, 49 (71.0%) exhibited submicroscopic abnormalities, with 94% concordance to prior biopsy findings. Among 15 arrested embryo samples, 6 (40%) showed submicroscopic abnormalities, while 3 (20%) were mosaic. Additionally, 138 developmentally arrested embryos, peripheral blood, and 1 abortive tissue were analyzed, achieving diagnostic accuracy exceeding 90%. Clinically, two couples with microdeletions/duplications had embryos successfully transferred, resulting in the birth of two healthy children. Conclusions The GenoLab M DX sequencer is a reliable, rapid (< 2 weeks), and cost-effective platform suitable for CNV analysis in monogenic diseases. It offers an innovative solution for cases involving de novo pathogenic variants or when family DNA samples are unavailable, representing a significant advancement in assisted reproduction.
- 13 December 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 67-79
Clinical application of preimplantation genetic testing for pathogenic microdeletion and microduplication based on an effective and convenient sequencing platform
Purpose PGT utilizing SNP-based linkage analysis for monogenic defects associated with microdeletions/duplications has been the standard method for preventing disease inheritance. However, its high cost and time consumption limit its accessibility. This study introduces a novel platform, the GenoLab M DX gene sequencer, designed to leverage next-generation sequencing (NGS) technology, aiming to reduce costs and increase sequencing efficiency in preimplantation genetic testing (PGT) for microdeletions/duplications. Methods Couples with microdeletion/duplication syndromes were recruited, and GenoLab was employed to detect copy number variations (CNVs) under 4 Mb in their abnormal blastocysts, developmentally arrested embryos, and peripheral blood, assessing the diagnostic validity of GenoLab. Results Blastocysts and arrested embryos from eight couples were thawed and sequenced using GenoLab. Of 69 affected blastocyst samples, 49 (71.0%) exhibited submicroscopic abnormalities, with 94% concordance to prior biopsy findings. Among 15 arrested embryo samples, 6 (40%) showed submicroscopic abnormalities, while 3 (20%) were mosaic. Additionally, 138 developmentally arrested embryos, peripheral blood, and 1 abortive tissue were analyzed, achieving diagnostic accuracy exceeding 90%. Clinically, two couples with microdeletions/duplications had embryos successfully transferred, resulting in the birth of two healthy children. Conclusions The GenoLab M DX sequencer is a reliable, rapid (< 2 weeks), and cost-effective platform suitable for CNV analysis in monogenic diseases. It offers an innovative solution for cases involving de novo pathogenic variants or when family DNA samples are unavailable, representing a significant advancement in assisted reproduction.
- Open Access
- 11 October 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 305, 119140
Cadmium disrupts IL6ST/STAT3 signaling involving FBXO2 in decidualization: Environmental trigger of spontaneous abortion
- 11 October 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 305, 119140
Open AccessCadmium disrupts IL6ST/STAT3 signaling involving FBXO2 in decidualization: Environmental trigger of spontaneous abortion
- 20 June 2025
- Published by MyJove Corporation
- No. 220,p. e68581
JoVE Video Dataset
Proteins are the primary executors of life activities and are regulated at transcriptional, translational, and post-translational modification (PTM) levels. Moreover, PTM represents a more complicated mechanism for regulating protein activities as a protein generally has various types of PTMs and multiple sites for a specific PTM. Plasmid transfection or lentivirus and adenovirus could be used in initial screening of the functionally important PTM site among all identified sites; however, these methods always face challenges such as low-efficiency in cell and tissue entry, time-consuming and high costs, potential immune reaction, etc. To address this, we recently developed and successfully employed a type of recombined peptide called TAT-PIP, TAT-conjugated PTM inhibitory peptide. TAT-PIP consists of a TAT module that facilitates cell and tissue entry and a PIP module that specifically downregulates the PTM at targeted sites through competitive binding. Here, we present a protocol that outlines the design specifications, quality control standards, and functional verification system of TAT-PIP. In the design section, we describe the consistency, the optional length, specificity, and conservation of TAT-PIP. Next, we introduce the quality testing requirements of TAT-PIP, which guarantee its efficacy and safety. In the application of the TAT-PIP part, we introduced the concentration gradient test of TAT-PIP, the incubation process of the tested cells, and the subsequent phenotypic detection. In summary, we describe an effective method for screening PTM sites by selectively knocking down a specific site and observing the resulting phenotype to infer its function. Due to its low synthetic cost and high efficiency, this method overcomes the limitations of existing technologies, such as plasmid transfection.
- 20 June 2025
- Published by MyJove Corporation
- No. 220,p. e68581
JoVE Video Dataset
Proteins are the primary executors of life activities and are regulated at transcriptional, translational, and post-translational modification (PTM) levels. Moreover, PTM represents a more complicated mechanism for regulating protein activities as a protein generally has various types of PTMs and multiple sites for a specific PTM. Plasmid transfection or lentivirus and adenovirus could be used in initial screening of the functionally important PTM site among all identified sites; however, these methods always face challenges such as low-efficiency in cell and tissue entry, time-consuming and high costs, potential immune reaction, etc. To address this, we recently developed and successfully employed a type of recombined peptide called TAT-PIP, TAT-conjugated PTM inhibitory peptide. TAT-PIP consists of a TAT module that facilitates cell and tissue entry and a PIP module that specifically downregulates the PTM at targeted sites through competitive binding. Here, we present a protocol that outlines the design specifications, quality control standards, and functional verification system of TAT-PIP. In the design section, we describe the consistency, the optional length, specificity, and conservation of TAT-PIP. Next, we introduce the quality testing requirements of TAT-PIP, which guarantee its efficacy and safety. In the application of the TAT-PIP part, we introduced the concentration gradient test of TAT-PIP, the incubation process of the tested cells, and the subsequent phenotypic detection. In summary, we describe an effective method for screening PTM sites by selectively knocking down a specific site and observing the resulting phenotype to infer its function. Due to its low synthetic cost and high efficiency, this method overcomes the limitations of existing technologies, such as plasmid transfection.
- 20 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68581
The Design and Application of Inhibiting Peptide for Rapid In vitro Downregulation of Post-Translational Modifications Levels at a Specific Site
Proteins are the primary executors of life activities and are regulated at transcriptional, translational, and post-translational modification (PTM) levels. Moreover, PTM represents a more complicated mechanism for regulating protein activities as a protein generally has various types of PTMs and multiple sites for a specific PTM. Plasmid transfection or lentivirus and adenovirus could be used in initial screening of the functionally important PTM site among all identified sites; however, these methods always face challenges such as low-efficiency in cell and tissue entry, time-consuming and high costs, potential immune reaction, etc. To address this, we recently developed and successfully employed a type of recombined peptide called TAT-PIP, TAT-conjugated PTM inhibitory peptide. TAT-PIP consists of a TAT module that facilitates cell and tissue entry and a PIP module that specifically downregulates the PTM at targeted sites through competitive binding. Here, we present a protocol that outlines the design specifications, quality control standards, and functional verification system of TAT-PIP. In the design section, we describe the consistency, the optional length, specificity, and conservation of TAT-PIP. Next, we introduce the quality testing requirements of TAT-PIP, which guarantee its efficacy and safety. In the application of the TAT-PIP part, we introduced the concentration gradient test of TAT-PIP, the incubation process of the tested cells, and the subsequent phenotypic detection. In summary, we describe an effective method for screening PTM sites by selectively knocking down a specific site and observing the resulting phenotype to infer its function. Due to its low synthetic cost and high efficiency, this method overcomes the limitations of existing technologies, such as plasmid transfection.
- 20 June 2025
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 220,p. e68581
The Design and Application of Inhibiting Peptide for Rapid In vitro Downregulation of Post-Translational Modifications Levels at a Specific Site
Proteins are the primary executors of life activities and are regulated at transcriptional, translational, and post-translational modification (PTM) levels. Moreover, PTM represents a more complicated mechanism for regulating protein activities as a protein generally has various types of PTMs and multiple sites for a specific PTM. Plasmid transfection or lentivirus and adenovirus could be used in initial screening of the functionally important PTM site among all identified sites; however, these methods always face challenges such as low-efficiency in cell and tissue entry, time-consuming and high costs, potential immune reaction, etc. To address this, we recently developed and successfully employed a type of recombined peptide called TAT-PIP, TAT-conjugated PTM inhibitory peptide. TAT-PIP consists of a TAT module that facilitates cell and tissue entry and a PIP module that specifically downregulates the PTM at targeted sites through competitive binding. Here, we present a protocol that outlines the design specifications, quality control standards, and functional verification system of TAT-PIP. In the design section, we describe the consistency, the optional length, specificity, and conservation of TAT-PIP. Next, we introduce the quality testing requirements of TAT-PIP, which guarantee its efficacy and safety. In the application of the TAT-PIP part, we introduced the concentration gradient test of TAT-PIP, the incubation process of the tested cells, and the subsequent phenotypic detection. In summary, we describe an effective method for screening PTM sites by selectively knocking down a specific site and observing the resulting phenotype to infer its function. Due to its low synthetic cost and high efficiency, this method overcomes the limitations of existing technologies, such as plasmid transfection.
- 30 January 2025
- Published by Elsevier in Toxicology
- Vol. 511, 154069
Cadmium induces spontaneous abortion by impairing endometrial stromal cell decidualization
- 30 January 2025
- Published by Elsevier in Toxicology
- Vol. 511, 154069
Cadmium induces spontaneous abortion by impairing endometrial stromal cell decidualization
- Open Access
- 16 October 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (10) , e70051
BIN2 inhibition suppress ovarian cancer progression meanwhile protect ovarian function through downregulating HDAC1 and RPS6 phosphorylation respectively
- 16 October 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (10) , e70051
Open AccessBIN2 inhibition suppress ovarian cancer progression meanwhile protect ovarian function through downregulating HDAC1 and RPS6 phosphorylation respectively
- 14 October 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (11) , 1-11
PARP1 acetylation at K119 is essential in regulating the progression and proliferation of cervical cancer cells
Cervical cancer, CC, is one of the malignant cancers in women worldwide. Many studies about the genesis and progression of CC have been done at genomic, transcriptional, translational, and epigenetic levels. However, much less is done at post-translational modification (PTM) level. We first used pan-PTM antibodies to compare the pan PTM levels between clinical normal cervical tissues and CC tissues; we then sent the selected samples for label-free identification of acetylation sites. Next, we employed WT or K119A mutant PARP1-EGFP-STREPII plasmid transfection in Hela cells and examined various indexes including colony formation, wound healing, ROS generation, early apoptosis, and immunofluorescence and quantification of proliferation markers (Ki67, PCNA, and p-P53). Last, we examined the levels of multiple important kinases regulating cervical cancer progression. We found that pan-acetylation was the most downregulated in clinical CC samples, whereas the acetylation of PARP1, Poly(ADP-ribose) polymerase-1, was upregulated at K119. Next, we showed that PARP1-WT overexpression significantly suppressed the proliferation and progression in CC cell line Hela, while K119A overexpression didn’t show any impact. Finally, PARP1-WT overexpression significantly decreased p-ERK1/2 while didn’t affect the phosphorylation levels of other important kinases such as AKT, MTOR, and RPS6. This study discovered a new type of PTM of PARP1 in CC, and showed that PARP1 acetylation at K119 is essential in regulating the proliferation and progression of CC through ERK1/2. Further studies are required to investigate how PARP1 acetylation impact its function.
- 14 October 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (11) , 1-11
PARP1 acetylation at K119 is essential in regulating the progression and proliferation of cervical cancer cells
Cervical cancer, CC, is one of the malignant cancers in women worldwide. Many studies about the genesis and progression of CC have been done at genomic, transcriptional, translational, and epigenetic levels. However, much less is done at post-translational modification (PTM) level. We first used pan-PTM antibodies to compare the pan PTM levels between clinical normal cervical tissues and CC tissues; we then sent the selected samples for label-free identification of acetylation sites. Next, we employed WT or K119A mutant PARP1-EGFP-STREPII plasmid transfection in Hela cells and examined various indexes including colony formation, wound healing, ROS generation, early apoptosis, and immunofluorescence and quantification of proliferation markers (Ki67, PCNA, and p-P53). Last, we examined the levels of multiple important kinases regulating cervical cancer progression. We found that pan-acetylation was the most downregulated in clinical CC samples, whereas the acetylation of PARP1, Poly(ADP-ribose) polymerase-1, was upregulated at K119. Next, we showed that PARP1-WT overexpression significantly suppressed the proliferation and progression in CC cell line Hela, while K119A overexpression didn’t show any impact. Finally, PARP1-WT overexpression significantly decreased p-ERK1/2 while didn’t affect the phosphorylation levels of other important kinases such as AKT, MTOR, and RPS6. This study discovered a new type of PTM of PARP1 in CC, and showed that PARP1 acetylation at K119 is essential in regulating the proliferation and progression of CC through ERK1/2. Further studies are required to investigate how PARP1 acetylation impact its function.